Argenx BV have informed MHRA that the Patient Information Leaflet (PIL) in the affected packs incorrectly contains reference to two subcutaneous injection sites. Only subcutaneous injection to the abdomen is permitted.
Important: This alert is gathered automatically for information only. Always refer to the original source and follow your practice’s own clinical governance procedures.
About this source
Alerts and Recalls for Drugs and Medical Devices - General Practice